<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764268</url>
  </required_header>
  <id_info>
    <org_study_id>HR-APTN-DT-AGC</org_study_id>
    <nct_id>NCT02764268</nct_id>
  </id_info>
  <brief_title>Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer</brief_title>
  <official_title>Apatinib Dose Titration: Analyses of Exposure, Safety and Efficacy in Advanced or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apatinib dose titration in Advanced or Metastatic Gastric Cancer
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose Interruptions</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE(Common Terminology Criteria for Adverse Events) v4.0</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>15 months</time_frame>
    <description>Number of Participants Who Reached Complete Response and Partial Response Assessed by Recist(Response Evaluation Criteria in Solid Tumors)1.1 at the End of the Second Treatment Cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>15 months</time_frame>
    <description>Number of Participants Who Reached Complete Response and Partial Response and Stable Disease Assessed by Recist(Response Evaluation Criteria in Solid Tumors)1.1 at the End of the Second Treatment Cycle.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 and ≤ 70 years of age

          2. Histological confirmed advanced or metastatic adenocarcinoma of the stomach

          3. Have failed for at least 2 lines of chemotherapy

          4. Life expectancy of at least 12 weeks

          5. Eastern Cooperative Oncology Group Performance Status of 0 or 1

          6. At least one measurable lesion beyond stomach (larger than 10 mm in diameter by spiral
             CT scan)

          7. Duration from the last therapy is more than 6 weeks for nitroso or mitomycin

          8. More than 4 weeks for operation or radiotherapy or cytotoxic agents

          9. Adequate hepatic, renal, heart, and hematologic functions

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix

          3. Hypertension and unable to be controlled within normal level following treatment of
             anti-hypertension agents (systolic blood pressure &gt; 140 mmHg, diastolic blood pressure
             &gt; 90 mmHg)

          4. Any factors that influence the usage of oral administration

          5. Evidence of central nerves system metastasis

          6. Intercurrence with one of the following: coronary artery disease, arrhythmia ,heart
             failure

          7. proteinuria ≥ (+)

          8. International Normalized Ratio &gt; 1.5 and activated partial thromboplastin time &gt; 1.5 ×
             Upper limit of normal（ULN）

          9. Certain possibility of gastric or intestine hemorrhage

         10. Less than 4 weeks from the last clinical trial

         11. Prior VEGFR inhibitor treatment

         12. Disability of serious uncontrolled intercurrence infection Objective evidence of
             previous or current pulmonary fibrosis history, interstitial pneumonia,
             Pneumoconiosis, radiation pneumonitis, drug-related pneumonia, Pulmonary function
             damaged seriously etc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yang Yao, MD</last_name>
    <email>yangyao_6@hotmail.com</email>
  </overall_contact>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>May 8, 2016</last_update_submitted>
  <last_update_submitted_qc>May 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Dose titration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

